Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Explore the following trends and analysis from our ‘Obesity’ market report:
- Understand the epidemiology, symptoms, diagnosis, and management of obesity, to get a better overview of the market.
- Annualized obesity market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the obesity therapeutics market.
- Comprehensive data assessing emerging trends and mechanisms of action under development for obesity treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
- Analysis of the current and future market competition in the global obesity therapeutics market.
- Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
How is our ‘Obesity’ report unique from other reports in the market?
- Develop and design your in-licensing and out-licensing strategies using a detailed overview of current pipeline products and technologies. This will help identify companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM obesity therapeutics market.
- Drive market revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM obesity therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
We recommend this valuable source of information to anyone involved in:
- Pharmaceutical/Biotech/Drug Manufacturing Industries (Big Pharma, Small Biotech, Start-ups, etc.),
- Pharmaceutical Industry Suppliers (e.g., Consulting Companies, CMOs, CDMOs, CROs, Technology Vendors)
- Consulting and Professional Services (e.g., Investment Companies, Investment Banks, Equity Companies, etc.)
- Pharma Manufacturers/Distributors (Innovative, Biotech, Generics, Biosimilars, Rare/Orphan Disease)
- Financial Institutions (Investors in Pharma/Biotech, Pricing Consultancies)/Parallel Trade Organizations
- Healthcare Organizations (HTA Bodies, Reimbursement Groups and Payers, Government Healthcare Organizations)
- Clinical Research Organizations (CROs)
To Get a Snapshot of the Obesity Market Report
Obesity Market Report Overview
The obesity market size across the 7MM was valued at $2.43 billion in 2021 and is expected to achieve a CAGR of more than 31% during 2021-2031. The US is anticipated to account for more than 74% of the global market which is mainly attributable to its large population, higher drug prices, and consistently high treatment rates. However, the country is likely to experience the slowest growth during the forecast period.
Obesity Market Outlook, 2021-2031 ($ Billion)
To gain more information about the obesity market forecast, download a free report sample
The obesity market research covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the obesity market through 2031.
Market Size (2021) | $2.43 billion |
CAGR (2021 – 2031) | >31% |
Key Drugs | Saxenda (liraglutide), Victoza (liraglutide) (OFF-LABEL), Liraglutide biosimilar, Wegovy (semaglutide), Ozempic (semaglutide) (OFF-LABEL) Tirzepatide, NN-9932 (oral semaglutide), Imcivree (setmelanotide), Setmelanotide hydrochloride ER, Xenical (Orlistat), Qsymia (phentermine + topiramate), and Generics |
Leading Players | Novo Nordisk, Eli Lilly, Pfizer, Boehringer Ingelheim, Zealand Pharma, OPKO Health, Versanis Bio Inc., Rhythm Pharmaceuticals, Roche, and H2-Pharma |
Obesity Market Drivers
Some of the major drivers of growth in the obesity market across the 7MM over the forecast period will include the entry of therapies with new routes of will administration, such as Novo Nordisk’s oral semaglutide (NN-9932), Eli Lilly’s orforglipron, and Pfizer’s PF-07081532, and danuglipron tromethamine. Greater awareness of obesity as a disease, rather than a lifestyle choice, will create an environment that favors convenient, efficacious therapies that can improve patient compliance rates and facilitate higher percentage weight loss in obese patients.
Obesity Market Segmentation by Drugs
Some of the key drugs in the US obesity market are Saxenda (liraglutide), Victoza (liraglutide) (OFF-LABEL), Liraglutide biosimilar, Wegovy (semaglutide), Ozempic (semaglutide) (OFF-LABEL) Tirzepatide, NN-9932 (oral semaglutide), Imcivree (setmelanotide), Setmelanotide hydrochloride ER, Xenical (Orlistat), Qsymia (phentermine + topiramate), and Generics.
In 2021, the market-leading drug was Novo Nordisk’s Ozempic, which is marketed for T2D and prescribed off label for obesity. It was followed by Novo Nordisk’s Wegovy and off-label Victoza.
Obesity Market Analysis by Drugs in the US, 2021 (%)
For more drugs insights into the US obesity market, download a free report sample
Obesity Market - Competitive Landscape
Some of the leading players in the obesity market are Novo Nordisk, Eli Lilly, Pfizer, Boehringer Ingelheim, Zealand Pharma, OPKO Health, Versanis Bio Inc., Rhythm Pharmaceuticals, Roche, and H2-Pharma.
Key Highlights
Report deliverables include a Word report and an Excel-based forecast model
Forecast includes the 7 major markets (7MM)
Forecast covers the period 2021-2031
• Drug sales in the obesity pharmacotherapy market are expected to grow by a significant margin between 2021 and 2031, with an overall compound annual growth rate (CAGR) of 31.3% over the forecast period, reaching $37.1 billion by 2031.
• Growth in the obesity market will be driven by the launch of 13 new pipeline products, including Novo Nordisk’s Wegovy (semaglutide), CagriSema (semaglutide + cagrilintide), and oral semaglutide (NN-9932), Eli Lilly’s tirzepatide, retatrutide, and orforglipron, Versanis Bio’s bimagrumab (BYM338), and Pfizer’s PF-07081532 and danuglipron tromethamine.
Eli Lilly
Pfizer
Boehringer Ingelheim
Zealand Pharma
OPKO Health
Versanis Bio Inc.
Rhythm Pharmaceuticals
Roche
H2-Pharma
Chelapharm
Vivus Inc.
Orexigen Therapeutics
Currax Pharmaceuticals
FUJIFILM Toyama Chemical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What was the obesity market size across the 7MM in 2021?
The obesity market size across the 7MM was valued at $2.43 billion in 2021.
-
What is the obesity market growth rate?
The obesity market is expected to achieve a CAGR of more than 31% during 2021-2031.
-
What are some of the key drugs in the US obesity market?
Some of the key drugs in the US obesity market are Saxenda (liraglutide), Victoza (liraglutide) (OFF-LABEL), Liraglutide biosimilar, Wegovy (semaglutide), Ozempic (semaglutide) (OFF-LABEL) Tirzepatide, NN-9932 (oral semaglutide), Imcivree (setmelanotide), Setmelanotide hydrochloride ER, Xenical (Orlistat), Qsymia (phentermine + topiramate), and Generics.
-
Who are the leading players in the obesity market?
Some of the leading players in the obesity market are Novo Nordisk, Eli Lilly, Pfizer, Boehringer Ingelheim, Zealand Pharma, OPKO Health, Versanis Bio Inc., Rhythm Pharmaceuticals, Roche, and H2-Pharma.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.